title: De novo Crohn's disease in a renal transplant recipient.
abstract: The prevalence of inflammatory bowel disease (IBD) after renal transplantation is affected by the immune tolerance and the modality of immunosuppression. Mycophenolate mofetil (MMF) may have a promoting effect on the development of posttransplantation erosive enterocolitis and a Crohn's disease-like pattern of colitis. We have presented a 40-year-old man with end-stage renal disease due to chronic glomerulonephritis who commenced hemodialysis for 2 months before receipt of a live unrelated renal transplant. He developed early posttransplantation diabetes mellitus and an anti graft rejection episode, which responded to a methylprednisolone pulse and OKT3 treatment. His immunosuppressive regimen included prednisolone, MMF, and tacrolimus. Three years after transplantation, he developed mild constitutional symptoms, mouth ulcerations, and chronic intermittent bloody diarrhea. Colonoscopy showed active segmental colitis with aphthous ulcers, involving the proximal descending colon and the splenic flexure. Colonic biopsies showed distended and branched crypts in the ascending colon, moderate active chronic colitis with regenerative atypia, skipping appearance, and ulceration in the splenic flexure and descending colon. The edematous crypts were associated with ulcerations in the sigmoid colon and rectum. The features were highly suggestive of Crohn's disease. He was successfully treated with high-dose steroids and 5-aminosalicylic acid. Subsequently, he developed chronic transplant glomerulopathy and restarted hemodialysis. We concluded that de novo Crohn's disease may develop in renal transplant recipients despite immunosuppressive therapy especially with MMF immunosuppression.
authors.affiliation: Hamed Al-Essa Organ Transplantation Centre and Faculty of Medicine, Kuwait University, Safat, Kuwait. medhatmohamed2000@yahoo.com
authors.forename: M A
authors.initials: MA
authors.lastname: Halim
authors.forename: T
authors.initials: T
authors.lastname: Said
authors.forename: P
authors.initials: P
authors.lastname: Nair
authors.forename: I
authors.initials: I
authors.lastname: Schmidt
authors.forename: A
authors.initials: A
authors.lastname: Hassan
authors.forename: K V
authors.initials: KV
authors.lastname: Johny
authors.forename: I
authors.initials: I
authors.lastname: Al-Muzairai
authors.forename: M
authors.initials: M
authors.lastname: Samhan
authors.forename: M R N
authors.initials: MR
authors.lastname: Nampoory
authors.forename: M
authors.initials: M
authors.lastname: Al-Mousawi
mesh_terms: D000328:Adult; D003424:Crohn Disease / Q000139:chemically induced / Q000473:pathology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D007668:Kidney / Q000473:pathology; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D011183:Postoperative Complications / Q000473:pathology; D006435:Renal Dialysis; D016559:Tacrolimus / Q000627:therapeutic use
chemical_list: D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid; D016559:Tacrolimus